ArticleRadiology case reports2026
Weekly MR-DWI/T1WI for early treatment response assessment of hepatic metastasis from ampullary carcinoma treated with gemcitabine, cisplatin, and durvalumab: A case report.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ampullary carcinoma is a rare gastrointestinal malignancy with a poor prognosis once hepatic metastasis develops. Although combination immunochemotherapy with gemcitabine, cisplatin, and durvalumab (GCD) therapy has recently demonstrated improved survival outcomes, early and accurate assessment of therapeutic response remains challenging. Magnetic resonance (MR) diffusion-weighted imaging (DWI), combined with T1-weighted imaging (T1WI), may provide a sensitive and noninvasive means of evaluating early treatment effects. A 68-year-old man underwent laparoscopic pancreaticoduodenectomy for ampullary carcinoma with lymph node metastasis. Despite adjuvant S-1 chemotherapy, a solitary 18-mm liver metastasis developed 6 months postoperatively. GCD therapy was initiated, and weekly MR-DWI/T1WI was performed for response assessment. At treatment initiation, the metastatic lesion had increased to 25 mm, demonstrating high signal intensity on DWI and low signal intensity on T1WI. Following treatment, rapid tumor regression was observed radiologically. Tumor volume decreased from 5.06 mm³ at baseline to 0.83 mm³ at 6 weeks and 0.53 mm³ at 10 weeks. FDG PET-CT and contrast-enhanced CT confirmed a complete radiological response after three treatment cycles. The patient remains recurrence-free 24 months after treatment completion. This case highlights the potential clinical value of weekly MR-DWI/T1WI for early and detailed assessment of treatment response during GCD therapy. Intensive MRI surveillance may support timely clinical decision-making and provide useful functional imaging biomarkers in selected patients with metastatic ampullary carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.